Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pentagastrin

FDA-approved product (injectable, injection), marketed as Peptavlon.

Registered studies
7
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pentagastrin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Pentagastrin. Its therapeutic class is shown instead.

WHO therapeutic group
Tests for gastric secretion
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli29.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pentagastrin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pentagastrin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A New Method for Determining Gastric Acid Output Using a Wireless Capsule

    NCT00702533 · start 2008-06-18

    Registered record
    Registry ID
    NCT00702533
    Conditions
    Gastric Acid Secretory Disorders
    Interventions
    Pentagastrin Injection BP; Pentagastrin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-06-18
    Completion
    Not recorded
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Acid Secretory Disorders
    InterventionPentagastrin Injection BP; Pentagastrin
    PhaseNot recorded
    Registry statusCompleted

  • An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

    NCT00629564 · start 2002-09

    Registered record
    Registry ID
    NCT00629564
    Conditions
    GERD
    Interventions
    Esomeprazole; Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-09
    Completion
    2002-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGERD
    InterventionEsomeprazole; Esomeprazole
    PhasePhase 4
    Registry statusCompleted

  • Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously

    NCT00635414 · start 2002-08

    Registered record
    Registry ID
    NCT00635414
    Conditions
    GERD
    Interventions
    Esomeprazole; Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-08
    Completion
    2002-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGERD
    InterventionEsomeprazole; Esomeprazole
    PhasePhase 4
    Registry statusCompleted

  • Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv

    NCT00626262 · start 2002-07

    Registered record
    Registry ID
    NCT00626262
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-07
    Completion
    2002-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionEsomeprazole
    PhasePhase 4
    Registry statusCompleted

  • Effect of Repeated Doses of YF476 on Stomach Acidity

    NCT01601405 · start 2001-10

    Registered record
    Registry ID
    NCT01601405
    Conditions
    Hypergastrinaemia
    Interventions
    YF476; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-10
    Completion
    2001-11
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypergastrinaemia
    InterventionYF476; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Effect of Single Doses of YF476 on Stomach Acidity

    NCT01601418 · start 2001-10

    Registered record
    Registry ID
    NCT01601418
    Conditions
    Hypergastrinaemia
    Interventions
    YF476; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-10
    Completion
    2002-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypergastrinaemia
    InterventionYF476; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Diagnosis and Treatment of Pheochromocytoma

    NCT00001229 · start 1988-10

    Registered record
    Registry ID
    NCT00001229
    Conditions
    Pheochromocytoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1988-10
    Completion
    2001-01
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPheochromocytoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted